Abstract:Abstract The human MHC class I -related chain gene A (MICA), a highly polymorphic MHC-encoded cell-surface glycoprotein, is a stress-induced and transformation related molecule absent from most normal tissues. Expression of MICA has been reported on a variety of mostly epithelial tumors. MICA can activate Natural Killer (NK) cells via interacting with the immunoreceptor NKG2D. Soluble MICA (sMICA), when shedded from tumor by the action of matrix-metalloproteinases (MMPs), can be detected at high levels in the sera of cancer patients. High levels of sMICA can down-regulate NKG2D expression and lead to functional impairment of NK cells thus providing for a mechanism of tumor escape. Gene array expression profiling of bone marrow biopsies revealed high levels of MMP2 and MMP9 in the bone marrow microenvironment, but not in the purified myeloma cells of the same patients. Since we are developing allogeneic NK cell therapy as a novel treatment for high-risk myeloma we decided to study whether the high activity of MMP2 and MMP9 resulted in 1) elevated sMICA levels in myeloma, and 2) affected NKG2D expression by NK cells. We found by ELISA assays that 28% (13/46) of patients with MM at diagnosis contained elevated serum levels of sMICA (median: 265.2 pg/ml; range: 125.9 – 806.5 pg/ml). sMICA levels were low in 16 control healthy donors tested (median: 0.8 pg/ml; range: 0 – 91 pg/ml). Next, we correlated sMICA levels with indicators of tumor burden and prognosticators of outcome in MM. We observed that sMICA levels in the serum of MM patients was not associated with Ras associated oncogene (RAN) expression, presence of abnormal cytogenetics, elevated CRP, elevated b2-microglobulin or elevated serum M-protein levels. There was also no correlation between MICA gene expression in purified MM cells and increased sMICA levels in the serum. We therefore examined several myeloma cell lines and found that high MICA gene expression does not always correlate with MICA expression at the cell surface as detected by flow cytometry. We hypothesize that the lack of correlation between MICA RNA expression and sMICA may be due to variation in translation of the MICA mRNA or failure to transport the MICA protein to the cell surface. Further, we tested the expression of NKG2D on CD3−/CD56+ cells of 5 MM patients with elevated sMICA serum levels and detected no down-regulation of NKG2D on NK cells compared to controls comprising MM patients with normal sMICA levels (n=3) or normal donors (n=5). Recent studies have suggested that tumor-membrane bound MICA may also play a role in the down-regulation of NKG2D on NK cells. We next incubated normal donor NK cells with a) the high membrane bound MICA expressing MM cell line U266 or b) serum from MM patients containing high MICA levels neither of which resulted in down-regulation of NKG2D. We conclude that despite the high expression of MMP2 and MMP9 both soluble or membrane bound MICA do not down-regulate NKG2D on NK cells and hence do not adversely affect NK cell function in MM. One explanation may be that the sMICA levels we found in myeloma patients were in the order of pg/ml, whilst the levels reported in epithelial tumors are 2–3 logs higher.

Tumor-Derived Soluble MICA Obstructs the NKG2D Pathway to Restrain NK Cytotoxicity.

A Bispecific Protein Rg7s-Mica Recruits Natural Killer Cells and Enhances NKG2D-mediated Immunosurveillance Against Hepatocellular Carcinoma

Prognostic value of soluble MICA levels in the serum of patients with advanced hepatocellular carcinoma.

Soluble And Membrane Bound Mica In Myeloma Do Not Adversely Effect Regulation Of Natural Killer Cell Function Via Nkg2d.

Tumor-derived Soluble MICs Impair CD3(+)CD56(+) NKT-like Cell Cytotoxicity in Cancer Patients.

The clinical and biological significance of MICA in clear cell renal cell carcinoma patients

The Opposite Effect of Mmica and Rmica on the Expression of NKG2D and the Influence on NK Cell Receptor Repertoire

Mica/B Expression is Inhibited by Unfolded Protein Response and Associated with Poor Prognosis in Human Hepatocellular Carcinoma

MICA immune complex formed with alpha 3 domain-specific antibody activates human NK cells in a Fc-dependent manner

Soluble MICA-NKG2D interaction upregulates IFN-γ production by activated CD3-CD56+ NK cells: potential impact on chronic graft versus host disease

Analysis of the expression of MICA on tumor cell lines of different histotypes and their sensitivity to NK cytotoxicity

Midkine Upregulates Mica/B Expression in Human Gastric Cancer Cells and Decreases Natural Killer Cell Cytotoxicity

Contact Inhibition Causes Strong Downregulation of Expression of MICA in Human Fibroblasts and Decreased NK Cell Killing

Data from Inhibition of MICA and MICB Shedding Elicits NK-Cell–Mediated Immunity Against Tumors Resistant to Cytotoxic T Cells

Soluble NKG2DLs Are Elevated in Breast Cancer Patients and Associate with Disease Outcome

NKG2D Immunoligand Rg7s-Mica Enhances NK Cell-mediated Immunosurveillance in Colorectal Carcinoma

An Anti-MICA/B Antibody and IL-15 Rescue Altered NKG2D-Dependent NK Cell Responses in Hepatocellular Carcinoma

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

Natural killer group 2D‐major histocompatibility complex class I polypeptide‐related sequence A activation enhances natural killer cell‐mediated immunity against hepatocellular carcinoma: A review

Heightened expression of MICA enhances the cytotoxicity of NK cells or CD8 + T cells to human corneal epithelium in vitro

The MICA-NKG2D axis in clear cell renal cell carcinoma bolsters MICA as target in immuno-oncology